News – Page 26 – Alligator Bioscience

2019-11-29

Alligator Bioscience AB appoints Chief Operating Officer

Lund, November 29, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX today announced that the company has appointed Dr Malin Carlsson as ...

2019-11-13

Lund, Sweden, November 13, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmace ...

2019-11-08

Preclinical Data Show that ALG.APV-527 is Well Tolerated with Repeated Dosing Preliminary in vivo Data Show that ALG.APV-527 has Potent Anti ...

2019-11-06

Lund, Sweden, November 6, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the company will present new preclinic ...

2019-10-24

Regulatory

"We are now regaining the exclusive, global rights to develop and commercialize ADC-1013 and at the same time receive enough ADC-1013 su ...

2019-08-20

Regulatory

Lund, Sweden, August 20, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that a license agreement has been reached wi ...

2019-07-31

Regulatory

Lund, Sweden, July 31, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that it has regained exclusive, worldwide righ ...

2019-07-11

Regulatory

Competitive safety data for ADC-1013. Significant events April-June• Janssen presented data from the clinical Phase I study with ADC-1013 in ...

2019-06-18

Lund, Sweden, June 18, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...